Across global biotech, less than 10% of drug candidates successfully reach commercialization.
Even more critically, ~70% of value is lost not in discovery — but in the transition from lab to market.

The Czech Republic is a perfect case study of this paradox.

It has:

• Deep medicinal chemistry expertise
• Strong academic institutions
• Growing biotech startup activity
• Established pharma manufacturing base

Yet the real opportunity — and bottleneck — lies in translation and commercialization.

This map breaks the ecosystem into 4 critical layers:

👉 Discovery Engines
👉 Therapy Builders
👉 Precision Diagnostics
👉 Clinical Translators

Because drug discovery doesn’t fail due to lack of science —
it fails due to lack of system orchestration across these layers.

🇨🇿 The Czech Drug Discovery Translation System

1. Discovery Engines

Where Czech Republic is strongest

This layer includes:

• IOCB Prague
• BIOCEV
• CEITEC
• Czech Academy of Sciences
• DIANA Biotechnologies
• i&i Prague

What’s working:

• World-class chemistry and molecular biology
• Strong public funding and infrastructure
• High-quality early-stage research output

The problem:

👉 Discovery is not the bottleneck anymore

The real issue is:

• Weak commercialization pathways
• Limited spinout scaling mechanisms
• Fragmented industry linkage

Insight:

Most discoveries never leave the lab — not because they lack value,
but because they lack commercial direction early enough.

2. Therapy Builders

Where value is created — and risk begins

This layer includes:

• SOTIO Biotech
• RIANA Therapeutics
• CasInvent Pharma
• Contipro
• Zentiva
• Oncomed

What’s working:

• Increasing number of biotech startups
• Oncology and immunotherapy strength
• Pharma heritage supporting development

The problem:

👉 This is where capital intensity spikes

Key gaps:

• Early-stage funding constraints
• Weak global investor visibility
• Limited scale-up infrastructure

Insight:

Czech startups often build strong science —
but struggle to position themselves for global capital markets.

3. Precision Diagnostics

The fastest-growing and most commercial-ready layer

This layer includes:

• GeneSpector
• Elphogene
• GHC Genetics
• BioVendor
• SPADIA
• SYNLAB

What’s working:

• Faster path to revenue vs therapeutics
• Strong clinical integration
• Scalable testing models

The problem:

👉 Diagnostics often operate in isolation

Gaps:

• Weak integration with drug pipelines
• Limited role in companion diagnostics strategy
• Underutilized in clinical trial acceleration

Insight:

Diagnostics should act as a bridge between discovery and commercialization —
but are often treated as standalone businesses.

4. Clinical Translators

The hidden layer that determines success or failure

This layer includes:

• IQVIA
• ICON
• Parexel
• FNUSA-ICRC
• CZECRIN
• Motol University Hospital

What’s working:

• Strong clinical trial infrastructure
• Access to patient populations
• Established CRO presence

The problem:

👉 This layer is under-leveraged strategically

Gaps:

• Poor coordination with early-stage startups
• Lack of integrated trial-to-commercial pathways
• Limited use for early validation

Insight:

This is where most biotech companies either de-risk — or die.

⚠️ The Core Problem: No Integrated System

Each layer works individually.

But biotech success depends on:

❌ Not discovery alone
❌ Not funding alone
❌ Not trials alone

👉 It depends on how well these layers are orchestrated together

🚀 The Real Opportunity: Build the Translation System

The winners in Czech biotech will be those who:

1. Align Discovery with Commercial Outcomes Early

• Define indication + market early
• Build with regulatory + payer endpoints in mind

2. Design Fundraising Around Milestones

• Not just science
• But de-risking events (clinical, regulatory, commercial)

3. Integrate Diagnostics into Therapeutic Strategy

• Companion diagnostics
• Patient stratification
• Trial acceleration

4. Use Clinical Infrastructure Strategically

• Not just for trials
• But for validation + market entry

🧩 The Missing Layer: Orchestration

This ecosystem doesn’t need more startups.
It doesn’t need more science.

👉 It needs orchestration across the stack

This is the gap where most companies fail.

And this is where the highest ROI opportunity exists.

📊 Why This Matters (For Founders & Investors)

• Faster time-to-clinic
• Higher probability of funding
• Better valuation at each stage
• Stronger exit potential

Without system alignment:

👉 Even great science fails commercially

⚡ Where GrowthVybz Fits

At GrowthVybz, we focus on:

• Commercialization strategy for biotech startups
• Investor-readiness and positioning
• Ecosystem mapping and GTM design
• Translation frameworks from lab → market

👉 Not more strategy decks
👉 But execution systems that connect the stack

If you're building or investing in Czech biotech:

The question isn’t “Is the science good?”
It’s:

👉 “Can this actually reach the market?”

📌 Final Takeaway

Czech Republic already has the ingredients:

✔ Discovery excellence
✔ Growing biotech ecosystem
✔ Clinical infrastructure
✔ Manufacturing base

But the real opportunity is:

👉 Turning this into a coordinated commercialization engine

📣 Call to Action

If you're a:

• Founder struggling with fundraising
• Investor evaluating biotech opportunities
• Ecosystem builder looking to unlock value

👉 Let’s build the missing layer: translation + commercialization system